Phaseline

Companies › Dr. F. Köhler Chemie

Dr. F. Köhler Chemie: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Gastroenterology, Other; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Custodiol-N Solution
Organ preservation solution for perfusion
–Phase 3Kidney Failure; Heart TransplantationJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06032195Custodiol-N SolutionPhase 2Heart TransplantationOtherJan 2027
NCT03627013Custodiol-N SolutionPhase 3Kidney FailureGastroenterologySep 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Albireo, an Ipsen Company GRIN Therapeutics Getz Pharma Huons Biopharma Neuren Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.